Results 111 to 120 of about 1,856,030 (259)
Gephyrin Neurological Autoimmunity
Gephyrin is a postsynaptic scaffold protein essential for inhibitory neurotransmission. Gephyrin‐immunoglobulin G (IgG) was reported, decades ago, in a single case of paraneoplastic stiff‐person‐like syndrome, but its broader clinical relevance remains unknown.
Maria Chiara Pantuliano +10 more
wiley +1 more source
Objective Both high and declining blood pressure (BP) are associated with risk of cognitive decline in older adults, and women have higher rates of hypertension and faster cognitive decline in late‐life. In old age, the relationship between changes in BP and changes in cognition is complex, and although sex differences in cognitive function and decline
Nicholas W. Baumgartner +4 more
wiley +1 more source
Objective Drug‐resistant epilepsy (DRE) remains a clinical challenge, as therapies modifying disease trajectory are lacking. Increasing evidence implicates gut microbiota dysbiosis in epilepsy pathophysiology, with short‐chain fatty acids (SCFAs) emerging as key microbial metabolites with neuroprotective and anti‐inflammatory properties.
Akash A. Bera +16 more
wiley +1 more source
Acute ischemic stroke due to large vessel occlusion is associated with rapid intravascular immune activation. Analysis of arterial blood sampled distal to the thrombus during mechanical thrombectomy revealed increased extracellular adenosine triphosphate (ATP) and interleukin‐1β (IL‐1β) levels, evidence of inflammasome priming in monocytes, and ...
Justine Münsterberg +33 more
wiley +1 more source
A new Patient‐Reported Outcome Scale to assess autoimmune Encephalitis: PROSE
Objective Autoimmune encephalitis (AIE) has long‐lasting effects. Generic clinical assessment‐scales insufficiently capture disease‐specific sequelae. Patient‐reported outcome measures (PROMs) assess outcomes important to patients, ensuring relevance in the clinic and trials.
Juliette Brenner +24 more
wiley +1 more source
The metabolic syndrome, a state of progressive metabolic dysfunction, injures the peripheral and central nervous systems, promoting peripheral neuropathy (PN) and cognitive impairment (CI), respectively. We posit PN and CI are connected in the metabolic syndrome framework, built on the premise that neurons, whether in the peripheral or central nervous ...
Masha G. Savelieff +3 more
wiley +1 more source
Perivascular Spaces as Determinants of Amyloid, Tau, and Vascular Biomarker Progression
Objective Magnetic resonance imaging (MRI)‐visible enlarged perivascular spaces (PVS) are markers of cerebral small vessel disease (SVD) and aging, processes implicated in both neurodegenerative and cerebrovascular pathologies. However, longitudinal positron emission tomography (PET) studies examining PVS as a mechanism underlying Alzheimer's disease ...
Audrey Low +11 more
wiley +1 more source
Objective Spinal muscular atrophy (SMA) is caused by deletions or mutations in the survival motor neuron 1 (SMN1) gene and subsequent reduction in the expression of survival motor neuron (SMN) protein. The disease is characterized by degeneration of α motor neurons and subsequent muscle atrophy.
Emma R. Sutton +4 more
wiley +1 more source
Genetic Modifiers of ABCA1 Activity Interact with APOE Isoforms to Mediate Alzheimer's Disease Risk
Objective ATP‐binding cassette transporter A1 (ABCA1) has been associated with Alzheimer's disease (AD), but the mechanisms by which it impacts disease risk are unknown. ABCA1 is known to bind apolipoprotein E (ApoE) and catalyze apolipoprotein lipidation.
Andrés Peña‐Tauber +24 more
wiley +1 more source
Objective Medication dose adjustments are common in treatment‐resistant epilepsy, but lack robust evidence, and patient‐reported seizure diaries have known limitations. We assessed whether ultra long‐term subcutaneous electroencephalogram (sqEEG) improves detection of seizure frequency changes after antiseizure medication adjustments.
Pedro F. Viana +20 more
wiley +1 more source

